These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23844359)

  • 1. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma.
    Kawai N; Miyake K; Yamamoto Y; Nishiyama Y; Tamiya T
    Biomed Res Int; 2013; 2013():247152. PubMed ID: 23844359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma].
    Kawai N; Miyake K; Okada M; Yamamoto Y; Nishiyama Y; Tamiya T
    No Shinkei Geka; 2013 Feb; 41(2):117-26. PubMed ID: 23378387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.
    Kawai N; Okubo S; Miyake K; Maeda Y; Yamamoto Y; Nishiyama Y; Tamiya T
    Ann Nucl Med; 2010 Jun; 24(5):335-43. PubMed ID: 20379859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography.
    Kim HO; Kim JS; Kim SO; Chae SY; Oh SJ; Seo M; Lee SH; Oh JS; Ryu JS; Huh JR; Kim JH
    Medicine (Baltimore); 2020 May; 99(20):e20140. PubMed ID: 32443328
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic role of (18)F-FDG PET for primary central nervous system lymphoma.
    Yamaguchi S; Hirata K; Kobayashi H; Shiga T; Manabe O; Kobayashi K; Motegi H; Terasaka S; Houkin K
    Ann Nucl Med; 2014 Aug; 28(7):603-9. PubMed ID: 24743915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating between Primary Central Nervous System Lymphoma and Glioblastoma: The Diagnostic Value of Combining
    Hatakeyama J; Ono T; Takahashi M; Oda M; Shimizu H
    Neurol Med Chir (Tokyo); 2021 Jun; 61(6):367-375. PubMed ID: 33967177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of intravoxel incoherent motion mr imaging in differentiating primary central nervous system lymphoma from glioblastoma multiforme.
    Yamashita K; Hiwatashi A; Togao O; Kikuchi K; Kitamura Y; Mizoguchi M; Yoshimoto K; Kuga D; Suzuki SO; Baba S; Isoda T; Iwaki T; Iihara K; Honda H
    J Magn Reson Imaging; 2016 Nov; 44(5):1256-1261. PubMed ID: 27093558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.
    Yamaguchi S; Hirata K; Kaneko S; Kobayashi H; Shiga T; Kobayashi K; Onimaru R; Shirato H; Tamaki N; Terasaka S; Houkin K
    Acta Neurochir (Wien); 2015 Feb; 157(2):187-94. PubMed ID: 25488176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.
    Kawai N; Nishiyama Y; Miyake K; Tamiya T; Nagao S
    Ann Nucl Med; 2005 Dec; 19(8):685-90. PubMed ID: 16444994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the Best Preoperative Quantitative Indicator to Differentiate Primary Central Nervous System Lymphoma from Glioblastoma?
    Inoue A; Matsumoto S; Ohnishi T; Miyazaki Y; Kinnami S; Kanno K; Honda T; Kurata M; Taniwaki M; Kusakabe K; Suehiro S; Yamashita D; Shigekawa S; Watanabe H; Kitazawa R; Kunieda T
    World Neurosurg; 2023 Apr; 172():e517-e523. PubMed ID: 36690204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
    Uchinomura S; Mitamura K; Norikane T; Yamamoto Y; Oishi A; Hatakeyama T; Miyake K; Nishiyama Y
    Nucl Med Commun; 2022 Mar; 43(3):270-274. PubMed ID: 34864812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
    Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
    Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
    Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
    Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients.
    Shi X; Zhang X; Yi C; Wang X; Chen Z; Zhang B
    Clin Nucl Med; 2013 Feb; 38(2):98-102. PubMed ID: 23334122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment.
    Kawai N; Zhen HN; Miyake K; Yamamaoto Y; Nishiyama Y; Tamiya T
    J Neurooncol; 2010 Nov; 100(2):225-32. PubMed ID: 20390437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [
    Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
    Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
    Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
    Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.